Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Xiaoping Yi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4220-1981; OpenAlex author ID A5003551877, A5138093421. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy. Co-author DOI 10.1002/mco2.70870↗
  2. Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. Co-author DOI 10.34133/research.0937↗
  3. Krüppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four … Co-author DOI 10.3892/ol.2017.6734↗
  4. KLF8 knockdown triggered growth inhibition and induced cell phase arrest in human pancreatic cancer cells. Co-author DOI 10.1016/j.gene.2016.03.025↗
  5. MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9. First author DOI 10.3892/mmr.2015.3294↗
  6. Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway. Co-author DOI 10.3892/mmr.2015.3380↗
  7. Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.3892/or.2013.2246↗
  8. [Simultaneous inhibition of XIAP and survivin expression on EMT and invasion of human pancreatic cancer cells]. First author DOI 10.3969/j.issn.1672-7347.2012.09.004↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Cheng · 2 shared papers, 2025–2026 · strength 0.42
  2. Yize Mao · 2 shared papers, 2025–2026 · strength 0.42
  3. Lizhi Liu · 2 shared papers, 2025–2026 · strength 0.42
  4. Qiuxia Yang · 2 shared papers, 2025–2026 · strength 0.42
  5. Yixiong Li · 3 shared papers, 2016–2025 · strength 0.35
  6. Shengping Li · 1 shared paper, 2026 · strength 0.23
  7. Wenzheng Li · 3 shared papers, 2015–2017 · strength 0.22
  8. Hongyan Zai · 3 shared papers, 2012–2017 · strength 0.20
  9. Xuejun Gong · 1 shared paper, 2025 · strength 0.19
  10. Ningning Niu · 1 shared paper, 2025 · strength 0.19
  11. Peng Luo · 1 shared paper, 2025 · strength 0.19
  12. Dong Luo · 1 shared paper, 2025 · strength 0.19
  13. LI Yi-xiong · 2 shared papers, 2015 · strength 0.13
  14. Tong Han · 2 shared papers, 2015 · strength 0.13
  15. Mujing Ke · 1 shared paper, 2015 · strength 0.06
  16. Bo Liu · 1 shared paper, 2015 · strength 0.06
  17. Jianlin Song · 1 shared paper, 2013 · strength 0.05
  18. Liping Cao · 1 shared paper, 2013 · strength 0.05
  19. Yixiong Li · 1 shared paper, 2013 · strength 0.05
  20. LÜ Xin-sheng · 1 shared paper, 2012 · strength 0.04
  21. Chun Ling Jiang · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.